EGFR tyrosine kinase inhibitors (EGFR-TKIs) treatment, demonstrating superior progression-free survival, higher tumor response rates and a better quality of life, are now recommended as the primary therapy for advanced-stage NSCLC patients with EGFR-activating mutations [5,6,7,8,9]. Here, EGFR is linked to non-small cell lung carcinoma.